Baxter International (NYSE: BAX) is a global medical technology company that provides essential healthcare products. Baxter International supports over 350 million patients each year. As highlighted by Business Wire, the CEO notes that Baxter International is making progress to stabilize the business and strengthen its performance for shareholders.
On April 30, 2026, Baxter International reported its first-quarter earnings. The company announced revenue of $2.70 billion, which is a 2.90% increase from the same period last year. This result surpassed the consensus analyst estimate of $2.62 billion, showing better-than-expected sales performance for the quarter.
The company’s earnings per share (EPS) was $0.36. While this figure is lower than the $0.55 reported in the same quarter a year ago, it beat the analyst estimate of $0.31. As highlighted by Zacks, this represents a positive earnings surprise of over 15% against market expectations.
Regarding its financial health, Baxter International has a debt-to-equity ratio of 1.60. The company’s liquidity appears strong with a current ratio of 2.31. A current ratio above one suggests a company has enough current assets, like cash and inventory, to cover its short-term debts.
